BioMarin Pharma (BMRN) Tops Q2 EPS by 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.57 -1.61%
EPS Growth %: +1,025.0%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +1,025.0%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $533.8 million versus the consensus estimate of $520.35 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.06-2.16 billion, versus the consensus of $2.11 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Marriott (MAR) Tops Q3 EPS by 19c; Guides EPS Higher
- Marriott shares rise 3% in premarket trade after raising full-year forecast
- Federal Realty Inv. Trust (FRT) Tops Q3 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
